Thermo Fisher Scientific Inc. $TMO Shares Sold by Compass Capital Management Inc.

Compass Capital Management Inc. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.2% in the fourth quarter, HoldingsChannel reports. The firm owned 114,283 shares of the medical research company’s stock after selling 22,167 shares during the period. Thermo Fisher Scientific makes up about 3.7% of Compass Capital Management Inc.’s portfolio, making the stock its 6th largest position. Compass Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $66,221,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in TMO. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $3,072,744,000. Wellington Management Group LLP grew its holdings in shares of Thermo Fisher Scientific by 88.9% during the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock valued at $1,309,292,000 after buying an additional 1,270,191 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Thermo Fisher Scientific by 21.0% during the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after buying an additional 1,028,125 shares during the last quarter. Nuveen LLC grew its holdings in shares of Thermo Fisher Scientific by 65.0% during the fourth quarter. Nuveen LLC now owns 2,147,296 shares of the medical research company’s stock valued at $1,244,251,000 after buying an additional 846,111 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 89.1% during the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock valued at $720,576,000 after purchasing an additional 825,649 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $475.12 on Friday. The firm has a market cap of $176.56 billion, a price-to-earnings ratio of 26.12, a P/E/G ratio of 2.13 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The firm’s 50-day simple moving average is $479.68 and its two-hundred day simple moving average is $528.09.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the previous year, the firm posted $5.15 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Thursday. They set a “neutral” rating and a $510.00 price target on the stock. Finally, KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $608.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.